Focus and Memory Research Peptides: Cognition Overview, Compound Classes and How to Choose

Cognition research peptides fall into two camps, a distinction most summaries overlook. The first camp comprises short regulatory peptides built from endogenous sequences — fragments of ACTH, analogues of tuftsin, derivatives of angiotensin IV — which adjust neurotrophin expression and neurotransmitter activity. The second comprises neurotrophic mimetics and peptide preparations extracted from brain tissue, aimed at synapse formation and neuronal survival. The camps diverge in mechanism, in the quality of supporting evidence and in the experimental models where each is appropriate. This guide treats them separately, compares the reference compounds and lays out a decision framework.

How cognition is measured in this field

Preclinical studies draw on a compact, well-validated toolkit. In rodents, spatial memory is tested with the Morris water maze or Barnes maze, recognition memory with novel object recognition, aversive learning with passive avoidance, and the anxiety component — which several of these compounds also affect — with the elevated plus maze or open field. At the molecular level, researchers quantify BDNF and NGF by ELISA or qPCR, record hippocampal long-term potentiation in brain slices, count dendritic spines after Golgi staining, and track dentate gyrus neurogenesis with markers such as doublecortin and BrdU uptake.

Where human studies exist, they rely on standard cognitive test batteries — except in the Russian clinical literature, which uses instruments and outcome measures that do not align neatly with Western trial practice. This mismatch complicates any reading of the Semax and Selank data; it is a genuine limitation, though not grounds to discard the work.

Compound classes used in this research

ACTH fragment analogues

Semax, Met-Glu-His-Phe-Pro-Gly-Pro (813.93 Da), is a heptapeptide assembled from ACTH(4-7) plus a Pro-Gly-Pro extension that protects it from enzymatic breakdown. Importantly, this design strips out the parent hormone's corticotropic activity, so central effects are obtained without stimulating the adrenal axis. Rodent studies describe fast, marked rises in hippocampal BDNF and its receptor TrkB within hours of dosing, as well as effects on dopaminergic and serotonergic signalling. N-Acetyl Semax Amidate carries an acetylated N-terminus and an amidated C-terminus, two routine modifications for prolonging resistance to exopeptidases.

Tuftsin analogues

Selank (751.89 Da) is a heptapeptide modelled on tuftsin, an immunomodulatory tetrapeptide, and likewise extended with Pro-Gly-Pro. Its reported profile is anxiolytic rather than stimulating, with proposed mechanisms including slowed enkephalin breakdown, altered expression of GABA-A receptor subunits and shifts in monoamine turnover. Researchers choose it when the question is how anxiety disrupts cognitive performance rather than cognition itself, which is why it is often studied alongside Semax.

Neurotrophic mimetics

Dihexa (439.55 Da), chemically N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, is an angiotensin IV derivative. Researchers at Washington State University reported that it enhances hepatocyte growth factor signalling through the c-Met receptor and boosts dendritic spine density and synapse formation in hippocampal cultures at picomolar concentrations. P-21 is a peptidergic compound derived from CNTF, investigated for adult hippocampal neurogenesis and raised BDNF, including in transgenic neurodegeneration models. PE-22-28, a spadin analogue originating from the sortilin propeptide, blocks the TREK-1 potassium channel — a distinctive, clearly defined target investigated chiefly in depression models rather than cognition models.

Brain-derived peptide preparations

Cerebrolysin is a mixture, not a single compound: a standardised enzymatic digest of porcine brain protein made up of low-molecular-weight peptides and free amino acids. It has been evaluated in registered clinical trials for stroke and dementia in Europe and Asia. Because of its composition, the analytical methods used for synthetic peptides do not apply — batch-to-batch consistency is a manufacturing matter rather than an HPLC purity value, and study designs should reflect this.

Evidence base, grouped by type of study

Cell culture and slice studies

Dihexa produces the clearest in-vitro result: new dendritic spines in hippocampal culture at very low concentrations, with c-Met dependence shown by blocking the receptor. Semax increases BDNF and TrkB expression both in cultured neurons and in hippocampal tissue. P-21 raises neurogenesis markers in vitro and in vivo. PE-22-28's inhibition of TREK-1 has been confirmed electrophysiologically, a more rigorous form of target validation than expression data provide.

Rodent studies

Russian research on Semax and Selank is extensive, spanning decades of learning, ischaemia and stress models. Dihexa has published data showing reversal of cognitive deficits in scopolamine and lesion models, and Cerebrolysin has a large body of rodent stroke and dementia work. Recurring weaknesses include inconsistent blinding, dependence on a single behavioural test and, for compounds of Russian origin, little replication by groups outside the original research network.

Human data

Semax and Selank hold marketing registration in Russia, and their clinical trial data appear mostly in Russian-language journals; neither is approved in the European Union or the United States. Cerebrolysin has the broadest international trial record on this page, including meta-analyses of stroke and vascular dementia trials that reach mixed conclusions. There are no human trial data whatsoever for Dihexa, P-21 or PE-22-28.

Side-by-side: reference compounds for cognition research

Noopept is listed as a small-molecule comparator rather than a synthetic peptide in the usual sense: it is a prolyl dipeptide ester, and its active metabolite is cycloprolylglycine, a dipeptide the body produces itself.

Selecting peptides for a focus and memory study

1. Are you studying cognition or affect? Semax and Dihexa are assessed with learning and synaptic endpoints, Selank and PE-22-28 with anxiety and mood endpoints. Giving an anxiolytic before a spatial memory task and reporting better scores may simply capture reduced stress interference, not improved memory.
2. Is there a defined molecular target? Dihexa's reliance on c-Met and PE-22-28's TREK-1 blockade permit receptor-level controls. Semax and Selank work through expression and turnover changes, so mechanistic conclusions are harder to close off.
3. Must the compound reach the brain across the blood-brain barrier? That is precisely why the Semax and Selank literature relies on intranasal delivery, and why pre-diluted nasal formats are available. Slice and culture experiments avoid the issue altogether.
4. Is the test material a single defined molecule? Cerebrolysin is a mixture with no single sequence or mass. Protocols treating it as one compound will not reproduce from batch to batch.

Every product for this goal is listed under peptides for focus and memory, with a narrower grouping under nootropic peptides. Our Semax vs Selank comparison covers the pairing researchers ask about most often.

Supply formats and handling

Lyophilised vials are the reference format and the only one in which the researcher sets the concentration at reconstitution. Pre-diluted nasal solutions — for example the NAD+ nasal format and corresponding Semax and Selank sprays — eliminate reconstitution error but lock in a fixed concentration and add a vehicle (preservative, tonicity agent, buffered pH) that has to be replicated in the control arm. Dissolving strips and capsules are offered for the orally bioavailable small molecules in this group; they are unsuitable for the peptides, which are broken down in the gastrointestinal tract.

On handling: position 1 of Semax is methionine, making the peptide prone to methionine oxidation, which appears as a satellite peak in the chromatogram and is a genuine degradation pathway in badly stored stock. Dihexa acts at picomolar levels in culture, so errors in serial dilution dominate the assay, and adding a carrier protein to the diluent is frequently required to limit loss through adsorption to plastic. Keep all lyophilised material sealed at -20 °C, shielded from light, and aliquot it on reconstitution instead of thawing it repeatedly.

Related compounds that appear in the same protocols

Several materials turn up next to these peptides in cognition studies despite having unrelated chemistry. Cortexin, like Cerebrolysin, is a peptide fraction extracted from brain tissue rather than a single defined molecule, and the same batch-characterisation caveat applies. Pinealon is a tripeptide from the Khavinson series investigated for neuronal endpoints; like the rest of that series, it has a large in-house literature and little external replication. Methylene blue features in cognition protocols because of its effect on neuronal bioenergetics rather than any neurotrophic action, and its biphasic concentration–response holds here just as in other settings. Bromantane (a small-molecule stimulant) and phenylpiracetam (a racetam) share only an application area with these peptides.

In practice, a literature search built around a marketing phrase rather than a mechanism collects compounds that cannot sensibly be compared. Organising by target — neurotrophin signalling, ion channels, monoamines, bioenergetics — gives a much more useful picture and matches what reviewers expect to see in a methods section.

Frequent study-design mistakes

The commonest mistake is drawing a conclusion from one behavioural task. A shift in performance on a single maze does not demonstrate a memory effect; adding a second task with a different underlying mechanism, plus a locomotor control, costs little yet is seldom done. A closely related trap is failing to separate reduced anxiety from improved cognition, which the anxiolytic compounds here make particularly easy to confuse.

The second is equating higher BDNF with a cognitive outcome. BDNF expression is a molecular intermediate rather than an endpoint, and it changes with handling stress, exercise and time of day, not just with the test compound.

The third is adsorptive loss with compounds active at picomolar levels. At such low concentrations peptides stick to polypropylene and glass, so without carrier protein or low-binding labware the concentration actually delivered may be only a fraction of the nominal value — yielding concentration–response curves that fail to reproduce and masquerade as biological variability.

The fourth is disregarding circadian timing. Hippocampal BDNF levels, the threshold for long-term potentiation and rodent performance in every standard maze all fluctuate over the day, and animals tested in their resting phase behave differently from those tested while active. Studies that neither fix nor report the testing window add variance that exceeds most of the effects under investigation.

Purity, identity confirmation and regulatory position

These synthetic peptides are short and should be supplied at 98% or higher by HPLC, with identity confirmed by mass spectrometry. For Semax in particular, check whether the chromatogram contains the oxidised-methionine satellite peak. For the acetylated and amidated variants, the mass shift relative to the parent is small yet clear-cut on a mass spectrum, and that is the only dependable way to verify that the modified molecule has been supplied. Cerebrolysin cannot be evaluated in this way; for it, manufacturing consistency is the relevant question.

Semax and Selank are registered medicines in Russia but are not approved in the European Union or the United States. Cerebrolysin holds approval in a number of countries, though not in the United States. Dihexa, P-21 and PE-22-28 are approved nowhere and lack any human trial data. All material referred to here is research-grade, for laboratory research only and not for human consumption.